A prescription digital therapeutic for ADHD can now be billed to Medicare under a specific code, something that was not true a year ago. That single change, buried inside the CY2026 Physician Fee Schedule final rule that CMS issued on October 31, 2025 and put into effect on January 1, 2026, is the most consequential reimbursement event this category has seen since the FDA began clearing these products.
The mechanism is a set of digital mental health treatment codes, G0552 through G0554, first created to pay for computerized behavioral therapy devices such as those used for substance use disorder and insomnia. For 2026, CMS extended that same code family to cover FDA authorized digital therapy devices indicated for ADHD, the device category defined under 21 CFR 882.5803. A clinician can now prescribe an authorized app based intervention, have the patient use it, and bill Medicare for the associated clinical management, in roughly the same way remote patient monitoring codes pay for the oversight work around a connected blood pressure cuff.
Why clearance alone was never enough
The pattern in digital therapeutics before this rule was consistent and painful for the companies building in the space. A product would clear FDA review, sometimes as a de novo authorization, demonstrating safety and a defined clinical benefit. Then it would launch into a market with no dedicated payment code, no established fee, and no consistent way for a prescribing clinician to be paid for the time spent recommending and monitoring it. Coverage decisions were made payer by payer and often plan by plan, which meant a product could be reimbursed for one employer's self funded plan and completely uncovered a state over. Several well known prescription digital therapeutics companies built strong clinical evidence and still struggled commercially because the unit economics of getting paid were worse than the unit economics of building the product.
Medicare adding a real, billable code changes that calculus for two reasons. First, Medicare rates set a reference point that commercial payers frequently anchor to, even when their own rates differ. Second, a Medicare code signals to health systems that digital therapeutics fit into existing workflows, coded and billed like any other covered service, rather than sitting outside the reimbursement system as a wellness perk.
The commercial side is starting to move too
Medicare is not acting alone. Commercial payers have begun to add explicit coverage for prescription digital therapeutics, including for substance use disorder indications, following a similar logic: an FDA authorized device with published clinical trial data is easier to underwrite than an unregulated wellness app, and paying for it can reduce downstream costs from untreated or undertreated conditions. This is the first time the reimbursement side of the industry has moved in step with the regulatory side, rather than trailing it by years.
There is also a legislative track worth watching. A bipartisan Senate bill would formally amend the Social Security Act to require coverage of prescription digital therapeutics under Medicare and Medicaid, rather than relying on CMS rulemaking that could change from one fee schedule cycle to the next. That bill has not passed, and operators should treat it as a signal of direction rather than settled policy, but its existence reflects how much attention this reimbursement gap has drawn on Capitol Hill.
What this means for operators
For companies building prescription digital therapeutics, the immediate task is aligning product indications with the specific device codes CMS has defined, since coverage is tied to the regulatory classification, not the broader category. For health systems, the opportunity is to build referral and monitoring workflows now, while the payment mechanism is new and competition for early adoption is limited. For investors, the fee schedule expansion is the first concrete evidence that a category known for clinical validation without commercial viability may be closing that gap, though one year of Medicare coverage is not proof of a durable business model.
The risk to watch is code utilization. A payment code only matters if clinicians actually use it, and DMHT codes have existed for insomnia and substance use disorder therapeutics for longer than the ADHD extension without generating large billing volumes. Whether the ADHD expansion produces meaningfully different uptake will depend on prescriber awareness, patient adherence to app based interventions, and whether the Medicare population, which skews older than typical ADHD treatment populations, is even the right test case. The next fee schedule cycle, expected around October 2026 for the 2027 rule, will show whether CMS treats this as the start of a broader expansion across other digital therapeutic categories or as a narrow, one time addition.
Key Signals
The CY2026 Medicare Physician Fee Schedule, effective January 1, 2026, extended digital mental health treatment codes G0552 through G0554 to FDA authorized ADHD digital therapy devices, the first Medicare coverage expansion of its kind for this device category. Commercial payers have begun adding parallel coverage for prescription digital therapeutics including substance use disorder indications, narrowing a reimbursement gap that has constrained the category commercially since its earliest FDA clearances. A Senate bill to codify Medicare and Medicaid coverage of prescription digital therapeutics remains pending and has not been enacted, so the durability of coverage still depends on annual CMS rulemaking. Operators should treat 2026 as the first real test of whether reimbursement, not clearance, is the binding constraint on this category's growth.
